Docetaxel is the only FDA-approved first-line treatment for castration-resistant prostate cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumour recurrence after an initial therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback